Streetbeat News

Price Targets

PACB

Morgan Stanley analyst Tejas Savant maintains an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) but lowers the price target from $4 to $2.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:34 pm

NFE

New Fortress Energy Inc. (NASDAQ:NFE) reported disappointing Q2 results, with losses of 41 cents per share and sales of $428.01 million, both missing analyst estimates. The company's Adjusted EBITDA was significantly below expectations due to delays in their FLNG 1 project. Analysts have subsequently slashed their price targets for NFE.

Portfolio Pulse from Avi Kapoor

August 12, 2024 | 5:34 pm

VCYT

Morgan Stanley analyst Tejas Savant maintains an Underweight rating on Veracyte (NASDAQ:VCYT) but raises the price target from $21 to $26.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:33 pm

AMC

Morgan Stanley has maintained its Underweight rating on AMC Entertainment Holdings (NYSE:AMC) and lowered the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:32 pm

VSTM

HC Wainwright & Co. analyst Sean Lee maintains a Buy rating on Verastem (NASDAQ:VSTM) but lowers the price target from $17.5 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:32 pm

RXO

Morgan Stanley analyst Ravi Shanker maintains an Equal-Weight rating on RXO (NYSE:RXO) and raises the price target from $19 to $26.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:30 pm

ABBV

Morgan Stanley analyst Terence Flynn maintains an Overweight rating on AbbVie (NYSE:ABBV) and raises the price target from $211 to $218.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:29 pm

WBTN

Deutsche Bank analyst Benjamin Black maintains a Buy rating on Webtoon Entertainment (NASDAQ:WBTN) but lowers the price target from $25 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:27 pm

BIOL

Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Biolase (OTC:BIOL) and maintained a price target of $0.4.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:26 pm

SEAT

Deutsche Bank analyst Benjamin Black maintains a Hold rating on Vivid Seats (NASDAQ:SEAT) and lowers the price target from $5.5 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:26 pm